Literature DB >> 21163140

Targeting Foxp3+ regulatory T cells-related immunosuppression for cancer immunotherapy.

Li-Li Feng1, Xin Wang.   

Abstract

OBJECTIVE: To review the current research into Foxp3(+) regulatory T cells (Treg) cell surface molecules, plasticity of Treg cells and mechanisms of Treg cell suppression and to explore the possibilities to interfere in Treg cell suppression of anti-tumor immunity. DATA SOURCES: A literature search of all English articles was performed on the online electronic PubMed database dated 1995 to 2010. The keywords searched included: CD4(+)CD25(+)Foxp3(+) regulatory T lymphocytes, cancer, and immunotherapy. After finding relevant articles within these search limits, a manual search was conducted through the references from these articles. STUDY SELECTION: Articles regarding the role of Treg cells in tumor immunity and the utility of Treg cells in tumor immunotherapy.
RESULTS: The results show that significant numbers of Treg cells are found in many tumors and it has been shown that the number of tumor infiltrating Treg cells correlates with adverse clinic outcomes. Treg cells are emerging as a key component of acquired tolerance to tumors.
CONCLUSIONS: Several mechanisms of immunosuppression can be mediated by Treg cell function. Distinct immunosuppressive molecules expressed by Treg cells or diverse molecules related to Treg induction or migration represent potential drug targets for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21163140

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  7 in total

1.  Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin's lymphoma patients.

Authors:  Mehdi Dehghani; Shokouh Sharifpour; Zahra Amirghofran; Hamid Reza Zare
Journal:  Med Oncol       Date:  2012-02-04       Impact factor: 3.064

2.  p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression.

Authors:  Yong Lu; Mingjun Zhang; Siqing Wang; Bangxing Hong; Zhiqiang Wang; Haiyan Li; Yuhuan Zheng; Jing Yang; Richard E Davis; Jianfei Qian; Jian Hou; Qing Yi
Journal:  Nat Commun       Date:  2014-06-24       Impact factor: 14.919

Review 3.  COX-2 and PGE2-dependent immunomodulation in breast cancer.

Authors:  Edward P Chen; Emer M Smyth
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-08-31       Impact factor: 3.072

Review 4.  Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions.

Authors:  Farhad Jadidi-Niaragh; Ghasem Ghalamfarsa; Mehdi Yousefi; Mina Hajifaraj Tabrizi; Fazel Shokri
Journal:  Tumour Biol       Date:  2013-05-17

Review 5.  Immune system: a double-edged sword in cancer.

Authors:  Bodduluru Lakshmi Narendra; Kasala Eshvendar Reddy; Saladi Shantikumar; Sistla Ramakrishna
Journal:  Inflamm Res       Date:  2013-07-19       Impact factor: 4.575

Review 6.  The Concept of Hormesis in Cancer Therapy - Is Less More?

Authors:  Andy Gaya; Charles A Akle; Satvinder Mudan; John Grange
Journal:  Cureus       Date:  2015-04-02

Review 7.  Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression.

Authors:  Ju-Ha Kim; Jisung Hwang; Ji Hoon Jung; Hyo-Jung Lee; Dae Young Lee; Sung-Hoon Kim
Journal:  Mol Cancer       Date:  2019-12-09       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.